Drug Search Results
More Filters [+]

Samidorphan

Alternative Names: samidorphan, rdc-0313, rdc0313, rdc 0313, alks-33, alks33, alks 33
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Samidorphan (SAM), a mu-opioid receptor antagonist, has gained interest due to its favorable pharmacokinetic and pharmacodynamic profile.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31523568/)

Mechanisms of Action: OPRM Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Sublingual

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: United States

Approved Indications: None

Known Adverse Events: None

Company: Alkermes
Company Location: DUBLIN 4 L2 00000
Company CEO: Richard F. Pops
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Samidorphan

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ALKS 3831-112

P1

Completed

Healthy Volunteers

2022-11-19

28%

Recent News Events